• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Sept. 9 Ocimum Biosolutions, an integrated genomics company, has announced that it has been awarded a US patent for ‘Molecular toxicology modelling’. The patent describes the changes in gene expression and identification of toxicity markers in tissues or cells exposed to a known renal (kidney) toxin.

The genes can be used as toxicity markers in drug screening. The invention, according to the company, includes a database of genes which are designed for use with microarrays and other solid-phase probes (which are playing a major role in genomics). In a press release, Ms Anu Acharya, CEO, Ocimum Biosolutions, said,

“We have consistently been in the forefront of genomics innovation over many years and this patent reiterates our strong commitment to continue as a leader in this space”. Genomics is the study and understanding of the genetic structure of a living form, the individual genes, their features and roles in the evolution of the human being or animal or plant species.

More Stories on : IPR | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line